Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation

Abstract

BackgroundMiR-182-5p, as a member of miRNA family, can be detected in lung cancer and plays an important role in lung cancer. To explore the clinical value of miR-182-5p in lung squamous cell carcinoma (LUSC) and to unveil the molecular mechanism of LUSC.MethodsThe clinical value of miR-182-5p in LUSC was investigated by collecting and calculating data from The Cancer Genome Atlas (TCGA) database, the Gene Expression Omnibus (GEO) database, and real-time quantitative polymerase chain reaction (RT-qPCR). Twelve prediction platforms were used to predict the target genes of miR-182-5p. Protein-protein interaction (PPI) networks and gene ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to explore the molecular mechanism of LUSC.ResultsThe expression of miR-182-5p was significantly over-expressed in LUSC than in non-cancerous tissues, as evidenced by various approaches, including the TCGA database, GEO microarrays, RT-qPCR, and a comprehensive meta-analysis of 501 LUSC cases and 148 non-cancerous cases. Furthermore, a total of 81 potential target genes were chosen from the union of predicted genes and the TCGA database. GO and KEGG analyses demonstrated that the target genes are involved in pathways related to biological processes. PPIs revealed the relationships between these genes, with EPAS1, PRKCE, NR3C1, and RHOB being located in the center of the PPI network.ConclusionsMiR-182-5p upregulation greatly contributes to LUSC and may serve as a biomarker in LUSC.

Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network

“…In the present study, ADAMTS9-AS2/has-mir-182/RECK axis and ADAMTS9-AS2/hsamir-182/CITED2 axis may construct a ceRNA network were closely to play a significant role in the progression of lung squamous cell carcinoma. Hsa-mir-182 upregulation greatly contributes to lung squamous cell carcinoma [46], which is the same as our results. A previous study shows that TTTY16 may act as a prognostic signature to cluster the patients with LUSC [47].…”

MiR-182-5p and its target HOXA9 in non-small cell lung cancer: a clinical and in-silico exploration with the combination of RT-qPCR, miRNA-seq and miRNA-chip

“…Studies also reported that the miRNA miR-182-5p participated in the occurrence and progression of various human cancers [25][26][27][28][29][30]. In previous work, we demonstrated a tumor-promoting effect of upregulated miR-182-5p in lung squamous cell carcinomas (LUSCs) [31].…”

“…Isolation and normalization of RNA, and the RT-qPCR were carried out as previously described [31][32][33][34][35][36][37][38]. RNU6B was selected as an endogenous control and reference gene of miR-182-5p [34].…”

“…The final analysis included data of 25 eligible miRNA-chips on 1656 NSCLC samples (LUAD, n = 350) and 948 noncancer samples. Several of the datasets that contained information on miR-182-5p expression in LUSC (GSE29248, GSE47525, GSE19945, GSE51853, and GSE74190) have been mined in previous work [31]. The characteristics of all the included miRNAchip data are listed in Table 5.…”

The Functional Effects of Key Driver KRAS Mutations on Gene Expression in Lung Cancer

“…Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) has redox homeostasis and can be used in the treatment of lung cancer (Nishimura et al, 2019). NR3C1 is reported to be involved in the pathways related to the biological process of lung cancer, and as a gene marker has a significant correlation with the survival of LUAD (Zhao et al, 2015;Luo et al, 2018). Cathepsin L1, as a protein was encoded by the CTSL1 gene, could reduce the cellular matrix and proteolytic cascades which resulting to promote invasion or metastatic activity (Duffy, 1996;Turk et al, 2012).…”